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Abstract For personalized medicine to be widely adopted
in clinical practice, stakeholders need evidence of effec-
tiveness, cost effectiveness and financial viability. Compar-
ative effectiveness research (CER) using population based,
retrospective data can inform assessments of personalized
medicine. The purpose of this paper is to explore the
potential and the limitations of CER. While the analytic
methods and data used for CER overcome many of the
disadvantages of randomized controlled trials, there are
significant barriers, including lack of routinely collected
genetic information, patient-reported outcomes and infor-
mation on new and emerging technologies. Recommenda-
tions for using CER include augmenting current data with
genetic information, promoting the collection of uniform
health outcomes, using value of information analysis to
guide development of new technologies, and greater use of
decision analysis. Finally, in order to address stakeholder
concerns regarding short term financial viability, additional
emphasis should be devoted to cost analysis of implemen-
tation costs and overall financial impact.
Keywords Personalized medicine . Comparative
effectiveness . Financial viability . Cost effectiveness
Introduction
Personalized medicine is facing an uncertain future. On one
hand, it is touted as the future of the healthcare system, an
approach that will yield safer, more effective, and less
costly medications and medical interventions [1]. On the
other hand, there are few clinical applications of personal-
ized medicine currently being implemented, and the
prognosis for future developments is unclear [2]. There
are a variety of reasons for the lack of widespread clinical
adoption [3], but the most immediate and compelling is that
the stakeholders—clinicians, funders, governments and
patients—do not have enough evidence that personalized
medicine approaches will yield significant health benefits
or reduced costs to justify investing or funding current
applications [4]. In an era of fixed budgets with limited
resources, the lack of clear evidence of the costs and health
gains is a significant barrier to the widespread development
and adoption of personalized medicine.
The lack of evidence on health outcomes is in part due to
the types of genetic markers that have been identified to
date. Whereas early proponents of personalized medicine
and genetic testing envisioned a world where people’s
future disease and health states could be assessed by taking
a sample of saliva (the ‘genetic scorecard’ [5]), the recent
progress in genetic influences on disease has had greater
success identifying multiple genetic predictors of disease,
often with low predictive power, than single gene links.
These low-penetrance, multiple genetic predictors compli-
cate research efforts to identify the effectiveness of new
treatments since large samples are needed to identify the
contribution of the genetic component to poor health
outcomes. In addition, the presence of multiple genetic
predictors makes it less likely that there will be simple and
clear interventions or pharmacogenetic treatments that will
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dramatically improve health outcomes. To date, it has
proven difficult to assess or demonstrate the effectiveness
of treatments based on personalized medicine using
randomized controlled trials [6].
In addition to the lack of evidence on the effectiveness of
new treatments, the economics of personalized medicine
have proven to be problematic [7]. Developing personalized
approaches can be more costly than traditional approaches
because personalized approaches must include the cost of
identifying genetic markers, of developing a genetic test,
and integrating the test into clinical practice. On the other
side, the expected revenue can be less than population-
based treatments since the market for personalized treat-
ments will be smaller (in the most extreme case, only the
individual) [3, 7], although population based treatments
may be faced with increased market pressure unless they
develop more effective treatments. For biotechnology and
pharmaceutical companies to invest in developing person-
alized approaches, there needs to be a clear indication from
third party payers (insurers or the government) or the public
that they will be willing to pay for these new approaches,
and perhaps subsidize their development. Given the lack of
evidence of increased effectiveness and/or cost savings, it is
not surprising that payers have been reluctant to commit to
funding the development of these new approaches [2, 8].
The lack of evidence of clinical utility and financial
viability has been identified as a significant barrier to the
widespread development and adoption of personalized
medicine [2, 4]. Previous researchers have also noted that
randomized controlled trials have significant limitations in
assessing the benefits of personalized medicine, including
insufficient sample sizes for conducting subgroup analysis,
limited time for follow-up, restrictive exclusion criteria and
limited ability to compare various treatment modalities [3].
Instead, researchers have advocated for the use of an
alternative methodology to assess the costs and effective-
ness of personalized medicine: Comparative effectiveness
research (CER) [1, 9–12]. CER has been defined as a
“rigorous evaluation of the impact of different options that
are available for treating a given medical condition for a
particular set of patients” [13]. While this definition is
flexible enough to incorporate most study methodologies,
in practice (at least in the United States, where funding has
significantly increased over the past several years) it has
primarily involved using retrospective data (e.g., SEER-
Medicare data) to examine the effectiveness (including,
perhaps, cost effectiveness) of alternative treatments in
actual practice. The evidence from CER tends to differ from
evidence from traditional randomized controlled trials in
that it includes a broader population (e.g., not subject to
exclusion criteria as in many RCTs), reflects the effective-
ness of how care is actually delivered in the real world (a
factor often highly controlled in most RCTs), can be used to
compare a variety of different treatment modalities, and can
include data for a longer period of time. Thus, CER has the
potential to overcome many of the limitations of RCTs in
providing evidence for the effectiveness and cost of
personalized medicine.
The purpose of this paper is to explore the potential and
the limitations of CER for providing evidence on the
effectiveness and financial viability of personalized medi-
cine. The discussion will not focus on the challenges and
opportunities from the standpoint of identifying new types
of genetic markers, but rather on the potential for
identifying evidence on effectiveness and cost of personal-
ized medicine. As such, particular attention is devoted to
identifying financial barriers to developing and implement-
ing personalized medicine, how comparative effectiveness
might provide evidence on long term costs and consequen-
ces, and the limitations of CER research. The paper
concludes with recommendations for using CER to facili-
tate the adoption of personalized medicine in the future.
Personalized medicine
Personalized medicine refers to ‘a tailored approach to
patient treatment based on the molecular analysis of
genetics, proteins and metabolites’ [3], or ‘care that relies
on any diagnostic method (genomic, phenotypic, proteo-
mic, imaging, etc.) that identifies personal characteristics to
target therapeutic interventions to those patients who may
disproportionally benefit from the treatment and/or im-
proved benefit-risk profile’ [14]. In other words, personal-
ized medicine aims to use information specifically about the
patient (as opposed to a broader information category such
as family history or ethnic group) to determine the
appropriate healthcare intervention. The intervention could
range from a common treatment given to many (such as
Warfrin) [15] to a medication tailored for the individual’s
genetic profile.
For a personalized treatment to be financially viable, the
expected revenue must outweigh the cost of developing and
administering the treatment. To illustrate the types of
personalized medicine and how they differ in potential
costs and revenue streams, consider the five cases outlined
in Table 1.
Risk assessment/screening (i and ii)
Tests for the purpose of identifying disease risk (rather than
diagnosis of an exciting condition or determining treatment)
are available for over 1700 conditions [16], with many
available directly to consumers. Consumers can purchase
information on their genetic risk for both future health
conditions (e.g., breast cancer and diabetes) and physical
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characteristics (e.g., eye color, muscle control and hair
thickness [17]) of themselves and predictions for their
offspring. This has raised concerns about the extent to
which the public will understand this information, how it
might be used, and whether a misunderstanding will cause
distress and lead to unnecessary diagnostic and follow-up
tests [18, 19].
For third-party payers (health insurers and government
funders), the value of this type of test depends upon
whether it will lead to reductions in future disease. If
there are preventive actions that can be taken (i), then the
cost of developing and administering the test might be
offset by future health savings and avoidance of future
illness. For instance, tests for the genetic variant associated
with breast cancer might lead to preventive measures
ranging from lifestyle (e.g., stop smoking) to a preventive
mastectomy. The benefit of these tests, and the extent to
which payers will cover the cost of the test and subsequent
treatments, depends upon the evidence of effectiveness in
preventing occurrence, the savings in associated future
healthcare costs, and the cost of developing and adminis-
tering the test. In theory, this might also lead to the
development of preventive genetically based treatments
such as more effective vaccines or medications to delay or
prevent onset of disease.
For many tests, however, there are no direct preventive
measures that can be taken. For instance, although genetic
tests are available for dementia, there are few effective
preventive treatments available to consumers. The value to
consumers from understanding their future risk is a topic of
much research. In some cases, the individual may value the
certainty associated with knowing that a condition will or
will not occur in the future (e.g., people with family history
of Huntington’s Disease finding out they do not have the
genetic marker). Payers (e.g., Medicare) have proven
reluctant to pay for these types of risk assessments to date,
so the primary source of revenue has come directly from
consumers [20]. That said, payers may be responsible for
subsequent diagnostic tests associated with individuals
worrying about the condition.
Diagnosis and treatment (iii and iv)
The third and fourth types of personalized medicine involve
the use of genetic information to help guide treatments of
existing conditions or estimate the prognosis of an existing
disease. As opposed to risk assessment or screening, which
might (in principle) be performed on the entire population,
personalized treatments are only for a subset of individuals
with a condition. This type of personalized medicine aims
to identify existing treatments that will have the greatest
impact (iii) or developing treatments tailored to the
individual (iv).
The financial viability of this type of personalized
approach depends upon the extent to which the new
treatments lead to fewer adverse events (reducing current
health spending) and better future health outcomes (future
cost savings) [21]. The most successful examples to date
have used genetic tests to determine which individuals
respond best (and worse) to an existing treatment (case iii).
Table 1 Overview of types of personalized medicines
Benefits to patient Costs Who pays? Testing and
treatment
Development Testing and treatment Cost savings
At time of
genetic test
In the
future
Genetic
test
Treatment Genetic
test
Treatment Adverse
events
Future
healthcare
costs
Third party
Payer
Patient Private
company
Screening/risk assessment
(i) Preventive healthcare
treatments available
+ + + + + − +
(ii) No preventive healthcare
treatments available
+? + + + +a +b
Diagnosis and treatment
(iii) Better use of existing
treatment
+ + + + + − − +
(iv) New drug or treatment + + + + + + − − +
Drug development
(v) Facilitate development
of other treatments
+ − + +
a Pay for future health costs
b Pay for genetic test
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For instance, a number of studies have examined using a
genetic test to identify patients with acute coronary
syndromes (ACS) with a reduced function allele
CYP2C19*2 (*2 allele) [22, 23]. As patients treated with
thienopyridines have an increased risk of adverse cardiac
events with clopidogrel, the genetic test is used to
determine who should get treated with prasugrel (a more
expensive treatment). If these savings are large enough to
offset the cost of giving the genetic test to patients with
ACS, then it will result in current cost savings.
It has been argued that this type of personalized
medicine is the most likely to yield significant health gains
and/or cost savings [7, 15]. Because this type of personal-
ized medicine uses existing treatments, there are no
treatment development costs. This approach offers the
potential of new life for drugs that have been eclipsed by
a newer class or found inadequate for general usage.
In contrast, there are relatively few examples of
personalized medicines involving treatments developed
specifically for a genetic condition or biomarker (case
iv). Unlike treatments involving existing drugs or inter-
ventions, this type of personalized medicine requires not
only developing the genetic marker and test, but also
incurring the cost of developing a genetic or molecular
based treatment. Because the developmental costs can be
significant, the number of potential patients small, and
current payment mechanisms not designed to reward
innovative tests or development of genetically based treat-
ments, this approach is seen as unlikely to yield a sig-
nificant number of new interventions in the near future
[14].
Drug development (v)
Finally, the fifth type of personalized medicine involves
using genetic or molecular information to help guide
selection of participants for treatment testing. It is hoped
that this approach will yield significantly faster and less
expensive testing of new treatments [7]. However, as the
primary benefits from this research are likely to fall to
companies who have developed the drugs, it is unlikely to
be paid for by payers. To date, this type of pharmacogenetic
application has been more efficient for some drugs, but has
not lead to a paradigm shift in the way drugs are developed
and tested [14].
Summary
The framework presented in Table 1 is not intended as a
comprehensive assessment of all types of personalized
medicine. Rather, it is intended to highlight the types of
information required to identify the benefits from the
personalized medicine, the factors influencing the costs,
and the sources of revenue. From this perspective, there are
a number of points to note:
& The benefits of preventive treatments emerging from
risk assessments (i) might require significant amount of
follow-up time in order to assess their effectiveness.
While this is a feature of many screenings, genetic tests
of conditions that will not be expressed until a much later
time (i.e., low immediacy) present special challenges;
& Risk assessments with no or ineffective preventive
treatments (ii) will not result in cost savings even in
the long run, and may be associated with other health
care costs when patients are distressed about their
genetic information. The benefits to the patient are
unlikely to be captured by traditional health outcomes;
& The benefits of personalized medicine using biomarkers
or genetic information to identify the most appropriate
treatment (iii and iv) can be assessed by comparing the
outcomes with existing (non-personalized) treatments;
& If personalized treatments are to result in cost savings (in
the short run), it will require significantly reducing the
number of adverse events and/or the cost of treatments.
As it is unlikely that personalized treatments (iv) will
cost less to develop and implement than existing treat-
ments, only those medical conditions associated with a
large numbers of people who experience significant
adverse events are likely to result in cost savings.
Comparative effectiveness research
At first glance, there would appear to be a conflict between
personalized medicine and CER. Whereas the goal of
personalized medicine is to produce a treatment tailored
for each individual, CER yields global assessments of the
average effectiveness of treatments across populations.
Since people respond differently to various treatments,
the goal should be to find the treatment that is right for
them, not the treatment that is right ‘on average’. For
instance, consider two drugs (A and B) with average levels
of effectiveness of 4 and 5, respectively (Fig. 1). If the
treatment decision was based on the average level of
effectiveness, the conclusion would be that B should be
recommended over A. But because there is variation in the
effectiveness, there are some individuals treated with B
who did worse than 4, and other individuals treated with A
who did better than 5. This raises the possibility that some
people might be better off being treated with A, others with
B, and looking for one favored treatment ignores the
potential benefits from personalizing treatment.
Advocates would say that such a conclusion (treat some
with Drug A, others with Drug B), is entirely consistent
with CER, it only requires performing subgroup analysis or
636 EPMA Journal (2010) 1:633–640
controlling for confounding variables during the analysis
[1, 9, 11, 24]. In fact, conducting CER with secondary,
claims data might actually augment and support personalized
medicine. Many of the challenges of assessing the costs and
benefits of personalized medicine using randomized con-
trolled trials are not present in CER analysis of secondary
datasets, including:
& Data is often available for many years before and after
events, thus allowing lengthy follow-up times;
& Datasets often contain large sample sizes, as is required
for subgroup analysis of personalized medicine;
& Information on type and cost of adverse events
requiring medical care is routinely collected;
& Population based data contains information on more
diverse populations than is usually available through
RCTs, thus making the results more reflective of the
population; and
& Information is typically available on a variety of treatment
modalities, not just the ones chosen for the RTCs.
But CER of retrospective data does have its limitations for
use in assessing the costs and effectiveness of personalized
medicine. First, there is often inadequate information on
health outcomes, particularly patient reported outcomes. Most
studies using secondary care data are limited to outcomes
measures that can be assessed with diagnostic codes or
mortality. More general quality of life measures, such as the
SF36 or disease-specific measures, are not routinely collected.
While this is an issue for nearly all studies that utilize
secondary care data, it is especially pertinent for personalized
medicine where the perceived value of genetic information to
the patient (e.g., from risk assessments) often goes beyond
health outcomes [25]. Ideally, these datasets would include
information on preference based assessments of the infor-
mation and intervention, including willingness-to-pay or
outcomes measured through discrete choice experiments.
Second, if comparative effectiveness is to be used for
subgroup analysis, then each individual’s data must be
linked to their genetic information. At present, genetic
information is not routinely recorded and it is difficult to
imagine that it be routinely available at anytime in the near
future. Not only would routine collection of genetic
information be costly and potentially inaccurate, but it
would raise significant privacy issues as genetic informa-
tion (by definition) is uniquely identifiable. While the FDA
in the US has recently encouraged manufacturers to collect
biomarkers data as part of the testing process [2], there are
significant hurdles that would need to be overcome before
recording of genetic information is routine.
Finally, using data from actual practice limits the scope
of CER to examining the effectiveness of treatments and
interventions that are already in use, not new or rarely used
treatments. In addition, claims-based data only record
interventions if they are reimbursed. New procedures may
not yet have specific reimbursement codes and thus may
not be recorded. Thus, CER may not be very useful for
examining the effectiveness of new treatments.
Analysis of retrospective data is not the only form of CER,
which can also include prospective trials and systematic
reviews. But prospective trials or data collection will be
subject to many of the same limitations as RCTs, including
restrictive samples and small sample sizes. Systematic reviews
and meta-analyses, while useful in consolidating and summa-
rizing the results of previous studies are unlikely to provide
systematic evidence on the costs and health outcomes
associated with many types of personalized medicines. While
CERmethods can assist in providing evidence for personalized
medicine, CER is unlikely to provide sufficient evidence of the
effectiveness and financial impacts of personalizedmedicine to
convince stakeholders to support widespread adoption.
Summary
CER has the potential to provide evidence for assessing the
effectiveness and cost effectiveness of personalized medi-
cine, but there are significant limitations that exist. The
usefulness of CER using secondary data will vary across
countries (which will have different types of data available),
but all will face the challenges of:
& Lack of patient reported outcomes;
& Lack of linked genetic or biomarker information; and
& Lack of evidence on new or not recorded personalized
approaches.
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Fig. 1 Comparative effectiveness
of two drugs
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Recommendations
For personalized medicine to be adopted by clinicians,
recognized by payers, invested in by private companies,
and accepted by consumers, there needs to be compelling
evidence of its effectiveness and financial viability. As was
argued above, such evidence is unlikely to come from
current research modalities. Developing evidence will
require both long and short term strategies and actions.
Ideally, evidence needed to determine the effectiveness and
cost effectiveness of personalized medicine, including patient
recorded and disease specific health outcomes, genetic
information, and characteristics of the clinical environment,
would be routinely collected and available to researchers
interested in developing new personalized approaches and
identifying the effectiveness of existing methods. Specifically,
developers of new personalized approaches would benefit
from being able to identify conditions where there is currently
sufficient variation in clinical effectiveness, cost and/or
adverse events from existing treatments, and this variation is
related to genetic markers in individuals.
The information provided by this analysis could inform
value of information (VOI) analysis to guide the future
development. VOI is intended to identify the net benefit that
would be received if all uncertainty regarding clinical utility
and costs was resolved. That is, it can be used to identify the
value from undertaking additional study or analysis. Previous
researchers have pointed out that this would be especially
useful for personalized medicine since the ultimate effective-
ness and cost effectiveness of the genetic markers depends
upon information on clinical outcomes (such as rate and cost
of adverse events) that is often not incorporated by basic
scientists when deciding which genetic marker to investigate
[10, 20]. Although VOI is widely used by biotechnology and
pharmaceutical companies, as well as by NICE in the UK,
formal recognition of its importance for personalized
medicine has been only recent.
The type of data described above would allow researchers
to identify areas where development of genetic markers or
tests might lead to improved health outcomes and be cost
effective. The data would also allow researchers to examine
the effectiveness and cost effectiveness of existing person-
alized medicine approaches. However, there are two areas
were additional evidence will be needed. First, regardless of
how comprehensive the datasets or effective the information
gathering, CER research using clinical data will not
supplement RTC in providing evidence on the effectiveness
of new interventions. But CER can augment RTCs by
identifying the types of genetic markers associated with
adverse events and long term health outcomes. Decision
modeling using information from RTCs and CER can then
explore the long term effectiveness and cost effectiveness of
the new treatments or tests.
Second, CER does not provide reliable evidence on the
cost of implementing personalized medicine into clinical
practice. It has been argued that implementation issues,
including the development of guidelines to facility change
in clinical management, coordination of laboratory testing
and communication of results, integration into clinical
practice and ways of communicating results to patients,
are substantial barriers to widespread adoption of person-
alized medicine in practice [4]. Information on the short
term net cost is particularly of interest to stakeholders
operating under budget constraints. Thus, CER research
may need to be accompanied by more regular analysis of
the costs and barriers to implementing personalized
medicine in practice.
Of course, while the above describes the ideal data that
would be available to conduct CER on personalized
medicine treatments and tests, no country currently has
large datasets on diverse populations that includes genetic
markers. So in the short term, researchers will need to find
ways to augment existing CER data will other types of data.
For instance, CER can be used to identify conditions with
significant adverse events, diverse treatment patterns and
having differential effects on specific populations that
might suggest the procedures are candidates for developing
personalized procedures. The outcomes from CER might be
liked with genetic data for specific populations and
information on the effectiveness of interventions from
RTC to inform decision modeling of outcomes and long
term results. While no substitute for more comprehensive
datasets, a combination of methods (CER to identify long
term outcomes, genetic information and RTCs to identify
short term response of specific populations, and decision
modeling to examine the long term effectiveness, cost
effectiveness and robustness of results) would provide a
way to enhance the evidence available on the effectiveness
and cost effectiveness of personalized medicine.
Summary
As countries will vary in the data that are available, the
recommendations will need to be tailored to each country.
But in general, recommendations for prompting assess-
ments of personalized medicine include:
& Link existing datasets to genetic information, ensuring
appropriate safeguards. While these might eventually be
collected for the population, in the short term, researchers
might seek to augment CER datasets on a case-by-case
basis;
& Promote the collection of uniform health outcomes,
including disease specific and patient reported outcome
measures. Again, in the short term, this might require
augmenting CER datasets on a case-by-case basis;
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& Value of information analysis using information from
CER is a useful tool for identifying personalized medicine
approaches that are likely to be accepted by stakeholders
and should be used more widely by basic scientists;
& Decision (e.g., Markov) models can be used to explore
the effectiveness and cost effectiveness of personalized
medicine by combining information from CER, RCTs
and systematic reviews; and
& To highlight the financial viability and impact on
stakeholders, researchers should look to include a cost
analysis focusing on short term costs or costs savings to
clinicians and other stakeholders.
Conclusion
For personalized medicine to fulfill expectations and alter
healthcare in fundamental ways, stakeholders need to
evidence that their investments in personalized medicine
will yield new procedures that dramatically improve health
outcomes and/or reduce adverse events. The purpose of this
paper was to examine the potential for CER to provide
evidence of effectiveness and financial viability. The
discussion highlighted the advantages that CER has over
other sources of information (RTCs), but also the limi-
tations of most current datasets that are used for CER. Until
comprehensive datasets linking genetic information, patient
reported outcomes, diagnostic codes or medical records,
and healthcare usage becomes available, researchers might
use decision modeling populated by CER and genetic
information to explore the impact of personalized medicine.
Calls for the use of CER to examine the impact of
personalized medicine have gained momentum in recent
years [1, 9, 11, 24], and previous researchers have
highlighted the potential for VOI to augment existing data
[10, 20]. The discussion here builds upon those studies by
examining in more detail the strengths and weaknesses of
using CER in conjunction with personalized medicine. The
overall conclusion here, that CER is valuable but is unlikely
to provide compelling evidence, is less optimistic than
previous studies. But the conclusions should not be viewed
as conflicting. Rather, this discussion is intended to highlight
the challenges that can be overcome by combining CER with
decision modeling and auxiliary data collection.
Implicit in these discussions is an assumption about how
the evidence from these studies will be used. Much of the
debate and controversy about CER stems from fears/hopes
(depending on one’s perspective) that it will be used to
determine which treatments are best for society, and that
only these will be made available to clinicians and patients.
This top-down approach to funding is actually very rare in
developed countries, even in the United Kingdom (where
NICE has recently been relegated from having authority in
determining treatments to merely making recommendations
for guidelines [26]). More common is for the results from
CER (or RTCs) to be used to inform guidelines or clinical
practice, but to leave clinicians and patients with some
degree of autonomy with regards to their treatment decisions.
A consequence of decentralizing decision making to the
individual/provider level (be it clinicians, patients, hospitals
or insurance companies) is that they may have a more
limited perspective. In a time of constrained budgets and
limited resources, providers and private insurers may have
fixed budgets and thus be unwilling to invest in procedures
that have significant short term financial costs and only
long term benefits (be it health gains or reduced future
spending). For this reason, providers may be less interested
in the results from cost effectiveness analysis than cost
analysis. Monitoring and reporting the cost of implement-
ing personalized medicine into clinical practice, including
the cost of training staff, changing information systems and
communicating complicated results to patients, are likely to
be more important than future health gains and savings in
implementing personalized medicine into regular clinical
practice. Though information from CER can inform the
discussion, a more formal cost analysis may ultimately need
to accompany studies examining the effectiveness and cost
effectiveness of personalized medicine.
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